Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation"
Ocul Immunol Inflamm
.
2019;27(1):71.
doi: 10.1080/09273948.2017.1379545.
Epub 2017 Oct 18.
Authors
Khayyam Durrani
1
,
John H Kempen
2
3
4
,
C Stephen Foster
3
5
6
;
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group
Affiliations
1
a Division of Ophthalmology , University of Connecticut Health , Farmington , Connecticut , USA.
2
b Department of Ophthalmology , Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.
3
c Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
4
d Discovery Eye Center , MyungSung Christian Medical Center and MyungSung Medical School , Addis Ababa , Ethiopia.
5
e Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.
6
f Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
PMID:
29043914
DOI:
10.1080/09273948.2017.1379545
No abstract available
Publication types
Comment
MeSH terms
Adalimumab
Humans
Inflammation*
Substances
Adalimumab